2024 Microbiome Market Trend

In the microbiome therapeutics market, some microbiome drugs have succeeded in commercialization. The microbiome market is growing not only in therapeutics but also in food-related markets. For example, consumers recognize probiotics as good for the body, and the food-related market is expected to form the largest share of microbiome applications due to the growing focus on health. 

BIOMICTRA, developed by BiomeBank, was approved by the Australian Department of Medicines and Medicines as a microbiome drug for recurrent C. difficile infections in 2022. In the U.S., Seres Therapeutics' SER-109 and Rebiotix's RBX-2660 received U.S. FDA approval and entered the market successfully in 2023.

On the other hand, Seres Therapeutics and Rebiotix have also succeeded in commercializing microbiome therapeutics but have recently laid off their products, and the burden of their development costs is also an issue.In addition, due to the growing awareness of gender neutrality, the number of diverse beauty products that meet consumer needs is increasing. Among them, skin microbiome products using probiotics and other products are growing their market share.

Furthermore, for the trend of carbon neutrality, projects are being developed globally for syngas fermentation using bacteria and converting them into useful substances such as ethanol. 

This report will cover the efforts of companies involved in the microbiome market. It will also cover a wide range of topics from market size, technology trends, sequencing, health food, agriculture, livestock and fisheries, skin care, industrial processes, and other applications, regulations, and marketing.

Countries Covered

• United States
• Canada
• Germany
• France
• United Kingdom
• China
• Japan
• India
• Others